Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925599 | 0.85 | MCHR1 (0.59) | MCHR1KCNH2ALDH1A1KDM4E | |
| SCHEMBL1573375 | 0.81 | HPGD (0.69) | KDM4EKMT2ATDP1HPGDSMN1; SMN2 | |
| SCHEMBL4925201 | 0.80 | MCHR1 (0.58) | MCHR1KCNH2 | |
| SCHEMBL27690410 | 0.80 | MCHR1 (0.59) | MCHR1KCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL5790478 | 0.80 | KDM4E (0.68) | KCNH2ALDH1A1KDM4EKMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL4922916 | 0.79 | MCHR1 (0.58) | MCHR1KCNH2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4923589 | 0.79 | MCHR1 (0.58) | MCHR1KCNH2SMN1; SMN2 | |
| Acetic Acid SCHEMBL4927369 | 0.78 | MCHR1 (0.63) | MCHR1KCNH2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4915340 | 0.76 | MCHR1 (0.55) | MCHR1KCNH2 | |
| SCHEMBL6028710 | 0.75 | GAA (0.65) | ALDH1A1KDM4EKMT2ATDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1831194-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068594-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 1440/4885ALDH1A1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.